Analytical Data
-
Gene name
TWEAK/TNFSF12
- Application
-
Alternative Names
APO3L; DR3LG; TWEAK; APO3 ligand; TNF-related weak inducer of apoptosis
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O54907
-
Expression Region
Gln53~His249
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TWEAK (TNFSF12) is a member of the tumor necrosis factor (TNF) superfamily, playing a crucial role in various biological processes, including cell proliferation, apoptosis, and inflammation. It primarily interacts with its receptor, Fn14, which is implicated in several pathophysiological conditions, such as cancer, autoimmune diseases, and tissue injury. Research on TWEAK/TNFSF12 recombinant proteins has garnered significant interest due to their potential therapeutic applications. These proteins can be utilized to study signaling pathways activated by the TWEAK-Fn14 interaction, contributing to a deeper understanding of disease mechanisms. Furthermore, recombinant TWEAK/TNFSF12 may serve as a valuable tool in drug development, providing insights into new treatments targeting diseases driven by aberrant Fn14 signaling. The modulation of immune responses and the promotion of wound healing are additional areas being explored, underscoring the protein's versatility and importance in both basic and translational research. Given the complexity of the immune system and the intertwining roles of TNF superfamily members, TWEAK/TNFSF12 stands out as a promising candidate for further investigation, with the potential to inform future therapeutic strategies addressing a range of disorders characterized by dysregulated signaling.
